First Time Loading...

Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 0.915 AUD 1.67% Market Closed
Updated: Apr 26, 2024

Intrinsic Value

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. [ Read More ]

The intrinsic value of one MSB stock under the Base Case scenario is 2.642 AUD. Compared to the current market price of 0.915 AUD, Mesoblast Ltd is Undervalued by 65%.

Key Points:
MSB Intrinsic Value
Base Case
2.642 AUD
Undervaluation 65%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Mesoblast Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MSB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Mesoblast Ltd

Provide an overview of the primary business activities
of Mesoblast Ltd.

What unique competitive advantages
does Mesoblast Ltd hold over its rivals?

What risks and challenges
does Mesoblast Ltd face in the near future?

Summarize the latest earnings call
of Mesoblast Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Mesoblast Ltd.

Provide P/S
for Mesoblast Ltd.

Provide P/E
for Mesoblast Ltd.

Provide P/OCF
for Mesoblast Ltd.

Provide P/FCFE
for Mesoblast Ltd.

Provide P/B
for Mesoblast Ltd.

Provide EV/S
for Mesoblast Ltd.

Provide EV/GP
for Mesoblast Ltd.

Provide EV/EBITDA
for Mesoblast Ltd.

Provide EV/EBIT
for Mesoblast Ltd.

Provide EV/OCF
for Mesoblast Ltd.

Provide EV/FCFF
for Mesoblast Ltd.

Provide EV/IC
for Mesoblast Ltd.

Show me price targets
for Mesoblast Ltd made by professional analysts.

What are the Revenue projections
for Mesoblast Ltd?

How accurate were the past Revenue estimates
for Mesoblast Ltd?

What are the Net Income projections
for Mesoblast Ltd?

How accurate were the past Net Income estimates
for Mesoblast Ltd?

What are the EPS projections
for Mesoblast Ltd?

How accurate were the past EPS estimates
for Mesoblast Ltd?

What are the EBIT projections
for Mesoblast Ltd?

How accurate were the past EBIT estimates
for Mesoblast Ltd?

Compare the revenue forecasts
for Mesoblast Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Mesoblast Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Mesoblast Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Mesoblast Ltd compared to its peers.

Compare the P/E ratios
of Mesoblast Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Mesoblast Ltd with its peers.

Analyze the financial leverage
of Mesoblast Ltd compared to its main competitors.

Show all profitability ratios
for Mesoblast Ltd.

Provide ROE
for Mesoblast Ltd.

Provide ROA
for Mesoblast Ltd.

Provide ROIC
for Mesoblast Ltd.

Provide ROCE
for Mesoblast Ltd.

Provide Gross Margin
for Mesoblast Ltd.

Provide Operating Margin
for Mesoblast Ltd.

Provide Net Margin
for Mesoblast Ltd.

Provide FCF Margin
for Mesoblast Ltd.

Show all solvency ratios
for Mesoblast Ltd.

Provide D/E Ratio
for Mesoblast Ltd.

Provide D/A Ratio
for Mesoblast Ltd.

Provide Interest Coverage Ratio
for Mesoblast Ltd.

Provide Altman Z-Score Ratio
for Mesoblast Ltd.

Provide Quick Ratio
for Mesoblast Ltd.

Provide Current Ratio
for Mesoblast Ltd.

Provide Cash Ratio
for Mesoblast Ltd.

What is the historical Revenue growth
over the last 5 years for Mesoblast Ltd?

What is the historical Net Income growth
over the last 5 years for Mesoblast Ltd?

What is the current Free Cash Flow
of Mesoblast Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Mesoblast Ltd.

Financials

Balance Sheet Decomposition
Mesoblast Ltd

Current Assets 85.2m
Cash & Short-Term Investments 77.1m
Receivables 4m
Other Current Assets 4m
Non-Current Assets 585.1m
Long-Term Investments 826k
PP&E 5.5m
Intangibles 576.6m
Other Non-Current Assets 2.2m
Current Liabilities 31.4m
Accounts Payable 10.8m
Accrued Liabilities 4m
Other Current Liabilities 16.6m
Non-Current Liabilities 130.2m
Long-Term Debt 110.6m
Other Non-Current Liabilities 19.6m
Efficiency

Earnings Waterfall
Mesoblast Ltd

Revenue
7.5m USD
Cost of Revenue
-21.7m USD
Gross Profit
-14.3m USD
Operating Expenses
-41.1m USD
Operating Income
-55.3m USD
Other Expenses
-17.7m USD
Net Income
-73.1m USD

Free Cash Flow Analysis
Mesoblast Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

MSB Profitability Score
Profitability Due Diligence

Mesoblast Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
ROE is Increasing
Negative 1-Year Revenue Growth
19/100
Profitability
Score

Mesoblast Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

MSB Solvency Score
Solvency Due Diligence

Mesoblast Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Positive Net Debt
56/100
Solvency
Score

Mesoblast Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MSB Price Targets Summary
Mesoblast Ltd

Wall Street analysts forecast MSB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MSB is 1.346 AUD with a low forecast of 0.555 AUD and a high forecast of 2.741 AUD.

Lowest
Price Target
0.555 AUD
39% Downside
Average
Price Target
1.346 AUD
47% Upside
Highest
Price Target
2.741 AUD
200% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

MSB Price
Mesoblast Ltd

1M 1M
+91%
6M 6M
+147%
1Y 1Y
+5%
3Y 3Y
-55%
5Y 5Y
-42%
10Y 10Y
-81%
Annual Price Range
0.915
52w Low
0.26
52w High
1.39
Price Metrics
Average Annual Return -9%
Standard Deviation of Annual Returns 35.05%
Max Drawdown -95%
Shares Statistics
Market Capitalization 1B AUD
Shares Outstanding 1 140 031 371
Percentage of Shares Shorted
N/A

MSB Return Decomposition
Main factors of price return

What is price return decomposition?

MSB News

Other Videos

Company Profile

Mesoblast Ltd Logo
Mesoblast Ltd

Country

Australia

Industry

Biotechnology

Market Cap

1B AUD

Dividend Yield

0%

Description

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The firm is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

Contact

VICTORIA
Melbourne
L 38 55 Collins St
+61396396036.0
http://www.mesoblast.com/

IPO

2004-12-16

Employees

83

Officers

Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Chief Medical Officer & Executive Director
Dr. Eric A. Rose M.D.
Interim Chief Finance Officer
Mr. Andrew Chaponnel B.Com.
General Counsel & Corporate Executive
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)
Head of Spinal Orthopedic Disorders
Mr. Roger D. Brown BA
Head of Pharma Partnering
Mr. Michael Schuster BSc, M.B.A., MS
Show More
Head of Regulatory Affairs & Quality Management
Ms. Geraldine Storton B.Sc., M.B.A., MMS
Head of Manufacturing
Mr. Justin Horst B.S.
Joint Company Secretary
Mr. Paul Hughes BPHARM
Show Less

See Also

Discover More
What is the Intrinsic Value of one MSB stock?

The intrinsic value of one MSB stock under the Base Case scenario is 2.642 AUD.

Is MSB stock undervalued or overvalued?

Compared to the current market price of 0.915 AUD, Mesoblast Ltd is Undervalued by 65%.